$0.55
+0.00 (+0.62%)
Open$0.57
Previous Close$0.55
Day High$0.57
Day Low$0.54
52W High$2.11
52W Low$0.40
Volume—
Avg Volume118.2K
Market Cap12.25M
P/E Ratio—
EPS$-0.30
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,353.1% upside
Current
$0.55
$0.55
Target
$8.04
$8.04
$5.03
$8.04 avg
$9.33
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.65M | 5.72M | 5.36M |
| Net Income | 307.3K | 283.7K | 353.7K |
| Profit Margin | 5.4% | 5.0% | 6.6% |
| EBITDA | 445.8K | 473.3K | 433.9K |
| Free Cash Flow | 346.8K | 407.6K | 312.1K |
| Rev Growth | +24.0% | +14.6% | +14.6% |
| Debt/Equity | 0.71 | 0.92 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |